ストックスクリーナーアプリを入手
1.935
3.74%
-0.085
前日終値:
$2.02
開ける：
$2.02
24時間の取引高:
86,872
Relative Volume:
0.21
時価総額：
$180.99M
収益：
-
当期純損益:
$1.60M
株価収益率:
64.50
EPS:
0.03
ネットキャッシュフロー:
$-62.91M
1週間 パフォーマンス:
-7.84%
1か月 パフォーマンス:
+26.27%
6か月 パフォーマンス:
+28.77%
1年 パフォーマンス:
-15.09%
1日の値動き範囲:
$1.935
$2.03
1週間の範囲:
$1.94
$2.205
52週間の値動き範囲:
$1.13
$2.66
Compugen Ltd Stock (CGEN) Company Profile
CGEN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CGEN
Compugen Ltd
|
1.935 | 188.94M | 0 | 1.60M | -62.91M | 0.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
475.43 | 120.31B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.19 | 81.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
851.63 | 53.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
351.50 | 46.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
345.88 | 37.20B | 4.98B | 69.59M | 525.67M | 0.5197 |
Compugen Ltd Stock (CGEN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-07 | 開始されました | H.C. Wainwright | Buy |
| 2025-01-13 | 開始されました | Oppenheimer | Outperform |
| 2022-08-05 | ダウングレード | Jefferies | Buy → Hold |
| 2020-05-26 | 再開されました | JMP Securities | Mkt Outperform |
| 2020-05-13 | 開始されました | Stifel | Buy |
| 2020-05-07 | 開始されました | SVB Leerink | Outperform |
| 2020-04-22 | 開始されました | ROTH Capital | Buy |
| 2020-03-24 | 開始されました | SunTrust | Buy |
| 2020-01-16 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-03-29 | 開始されました | Oppenheimer | Outperform |
| 2016-02-01 | 再開されました | Oppenheimer | Outperform |
| 2015-10-15 | 開始されました | FBR Capital | Outperform |
| 2015-04-23 | 再開されました | Jefferies | Buy |
| 2015-04-21 | 開始されました | Oppenheimer | Outperform |
| 2014-02-07 | 開始されました | MLV & Co | Buy |
| 2009-12-28 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2009-07-29 | 開始されました | Cantor Fitzgerald | Buy |
すべてを表示
Compugen Ltd (CGEN) 最新ニュース
Compugen (NASDAQ:CGEN) Stock Price Crosses Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Can Compugen Ltd. maintain sales growthHead and Shoulders Patterns & Small Budget Wealth Tips - bollywoodhelpline.com
Aug Opening: Can Fidelis Insurance Holdings Limited stock outperform in a bear marketRate Hike & Stepwise Trade Execution Plans - baoquankhu1.vn
Compugen (NASDAQ:CGEN) Stock Price Passes Above 200 Day Moving AverageWhat's Next? - MarketBeat
Can Compugen Ltd maintain sales growthEarnings Growth Summary & Stock Portfolio Risk Management - baoquankhu1.vn
Update Recap: Can Compugen Ltd stock continue upward trendPortfolio Value Report & Smart Money Movement Alerts - Bộ Nội Vụ
Targets Report: Will Compugen Ltd stock outperform tech sector in 2025July 2025 Volume & High Win Rate Trade Tips - Bộ Nội Vụ
Compugen shares jump after $65 million royalty monetization deal with AstraZeneca - MSN
Why Compugen Ltd. stock could benefit from AI revolutionRate Cut & Intraday High Probability Alerts - Улправда
Brokers Issue Forecasts for Compugen FY2025 Earnings - Defense World
HC Wainwright Estimates Compugen FY2025 Earnings - MarketBeat
Comparing Compugen (NASDAQ:CGEN) & Psyence Biomedical (NASDAQ:PBM) - Defense World
Compugen (NASDAQ:CGEN) Coverage Initiated at HC Wainwright - Defense World
Compugen rises on royalty deal with AstraZeneca - MSN
How buybacks impact Compugen Ltd. stock valueRate Hike & Capital Efficiency Focused Strategies - Улправда
Why Compugen Ltd. stock could rally in 2025Quarterly Portfolio Review & AI Optimized Trading Strategy Guides - Улправда
Will Compugen Ltd. stock benefit from infrastructure spending2025 Dividend Review & Low Volatility Stock Suggestions - Улправда
Compugen (NASDAQ:CGEN) Stock Rating Upgraded by HC Wainwright - MarketBeat
Is Compugen Ltd. stock a bargain at current levelsMoving Average Strategies & Expert-Backed Recommendations That Deliver - Улправда
H.C. Wainwright initiates coverage on Compugen stock with Buy rating By Investing.com - Investing.com Nigeria
Compugen (CGEN): HC Wainwright Initiates Coverage with 'Buy' Rat - GuruFocus
H.C. Wainwright initiates coverage on Compugen stock with Buy rating - Investing.com
This Applied Digital Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Benzinga
HC Wainwright & Co. Initiates Coverage of Compugen (CGEN) with Buy Recommendation - Nasdaq
Operating cash flow per share of Compugen Ltd. – TASE:CGEN - TradingView — Track All Markets
Will Compugen Ltd. stock benefit from sector rotationWeekly Profit Summary & Daily Growth Stock Tips - Улправда
Is Compugen Ltd. stock a defensive play in 2025Portfolio Gains Summary & Real-Time Volume Analysis Alerts - Улправда
Can Compugen Ltd. stock deliver strong Q4 earningsJuly 2025 Analyst Calls & Safe Capital Growth Stock Tips - Улправда
Compugen stock soars on $65 million AstraZeneca royalty deal By Investing.com - Investing.com Australia
Compugen Secures $90 Million in a Strategic Royalty Monetization Deal with AstraZeneca - TipRanks
Compugen (CGEN) Rises on Royalty Deal with AstraZeneca - GuruFocus
Compugen restructures AstraZeneca deal to boost cash coffers - גלובס
Compugen stock soars on $65 million AstraZeneca royalty deal - Investing.com
Compugen Monetizes Portion of Cancer Treatment Future Royalties to AstraZeneca for Up to $90 Million - marketscreener.com
Compugen rises on royalty deal with AstraZeneca (CGEN:NASDAQ) - Seeking Alpha
Compugen monetizes portion of cancer drug royalties to AstraZeneca By Investing.com - Investing.com South Africa
Compugen monetizes portion of cancer drug royalties to AstraZeneca - Investing.com
Compugen monetizes portion of rilvegostomig future royalties to AstraZeneca for up to $90 million - marketscreener.com
Compugen Ltd. and Medimmune Limited Enter into Amendment Number 4 to the License Agreement - marketscreener.com
Compugen Monetizes Portion Of Rilvegostomig Future Royalties To Astrazeneca For Up To $90 Million - TradingView — Track All Markets
[6-K] COMPUGEN LTD Current Report (Foreign Issuer) | CGEN SEC FilingForm 6-K - Stock Titan
Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million - marketscreener.com
Cancer immunotherapy royalty deal brings biotech up to $90M in funding - Stock Titan
Revenue per share of Compugen Ltd. – TASE:CGEN - TradingView — Track All Markets
Compugen Ltd (CGEN) 財務データ
収益
当期純利益
現金流量
EPS
0.28%
2.60%
大文字化:
|
ボリューム (24 時間):